Companies: 10,795·Total market cap: $144.5T
HCA Healthcare, Inc.

HCA Healthcare, Inc.

HCANYSEHealthcare● Active
$372.13
+$10.30(+2.85%)
Market Cap$82.6B
P/E Ratio
52W High$556.52
52W Low$330

HCA Healthcare, Inc. (HCA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

hca · stock forecast · 46 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 46 Wall Street analysts in the past 3 months

SellBuy

Buy

46 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
30
Hold
14
Sell
2
Strong Sell
0
Total: 46 · Buy rate: 65.2%

12-Month Price Target

High

$635

Consensus

$505

+35.6% upside

Low

$413

Median: $520 · Last Close: $372.13

The HCA Healthcare, Inc. (HCA) analyst consensus is Buy, based on ratings from 46 Wall Street analysts over the past 3 months. The average 12-month HCA price target is $504.73, representing +35.6% upside from the current price of $372.13.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $505 (35.6%)

Consensus Target

$504.73

35.6% upside

High Target

$635

70.6%

Low Target

$413

11.0%

Current Price

$372.13

as of today

Based on analyst price targets, the HCA stock price prediction for the next 12 months ranges from $413 to $635. The consensus HCA price forecast of $504.73 implies 35.6% upside from the current price of $372.13.

Short-Term Price Prediction

Bear

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$353.525.00%

1-day model range: $352.13–$354.91. Peak: $354.91 (-5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$486+30.7%
2028$583+56.7%
2029$659+77.1%
2030$714+92.0%
2031+102.5%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

21%0%79%
3Buy
0Neutral
11Sell
RSI (14)15.8Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · HCA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$367.10BUY
MA 10$377.71SELL
MA 20$398.41SELL
MA 50$439.33SELL
MA 100$474.53SELL
MA 200$461.68SELL
Current $HCA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$370.03BUY
EMA 10$378.09SELL
EMA 20$394.64SELL
EMA 50$429.49SELL
EMA 100$450.70SELL
EMA 200$446.78SELL
Current $HCA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Bernstein2026-06-04
Maintains
Market PerformMarket Perform
TD Cowen2026-04-27
Maintains
BuyBuy
RBC Capital2026-04-27
Maintains
OutperformOutperform
Wells Fargo2026-04-27
Maintains
Equal WeightEqual Weight
Stephens & Co.2026-04-27
Maintains
OverweightOverweight
Barclays2026-04-27
Maintains
OverweightOverweight
Oppenheimer2026-04-27
Maintains
OutperformOutperform
Truist Securities2026-04-27
Maintains
BuyBuy
Keybanc2026-04-27
Maintains
OverweightOverweight
TD Cowen2026-03-10
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on HCA Healthcare, Inc. (HCA) stock. Of the recent 413 rating actions, 19 were upgrades and 29 were downgrades. 46 analysts currently cover HCA.

Analyst Recommendation Trends

Buy ratings101
Hold ratings01↑ +1
Sell ratings101

HCA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$78.5B

↓ 9.5% YoY

Revenue Next Year

$82.3B

↑ 4.8% YoY

EPS This Year

$30.18

EPS Next Year

$33.19

↑ 10.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast HCA EPS of $30.18 for the current fiscal year, based on estimates from 16 analysts. The HCA revenue forecast is $78.5B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The HCA stock forecast is supported by two independent data sources: analyst consensus ratings from 46 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus HCA price target is $504.73 (+35.6% upside), with an analyst consensus of Buy.

The HCA short-term stock prediction for tomorrow is $353.52 (-5.00%). The HCA stock price prediction for 2027 estimates an average of $486. The HCA stock prediction for 2030 projects a range of $691–$738.

HCA Healthcare, Inc. trades on NYSE under the ticker HCA. The HCA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 65% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

HCA forecast · 8 questions

According to 46 Wall Street analysts, the average 12-month HCA price target is $504.73, with a high forecast of $635.00 and a low of $413.00. The median price target is shown in the chart above when available. This implies +35.6% potential upside from the current price of $372.13.

HCA price targetWhat is HCA price targetHCA analyst price targetHCA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.